P Geborek

Summary

Affiliation: Lund University Hospital
Country: Sweden

Publications

  1. pmc Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
    P Geborek
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Ann Rheum Dis 64:699-703. 2005
  2. pmc Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden
    P Geborek
    Department of Rheumatology, Lund University Hospital, S 221 85 Lund, Sweden
    Ann Rheum Dis 61:793-8. 2002
  3. doi request reprint Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 47:495-9. 2008
  4. doi request reprint Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden
    A Gulfe
    Department of Rheumatology, Lund University Hospital, Sweden
    Ann Rheum Dis 69:352-7. 2010
  5. doi request reprint Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register
    J A Karlsson
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 47:507-13. 2008
  6. doi request reprint Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register
    L E Kristensen
    South Sweden Musculoskeletal Research Centre, Lund University Hospital, Lund University, Sweden
    Arthritis Care Res (Hoboken) 62:1362-9. 2010
  7. doi request reprint Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis
    K Eberhardt
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Scand J Rheumatol 37:109-12. 2008
  8. ncbi request reprint Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients
    M C Kapetanovic
    Department of Rheumatology, Lund University Hospital, Kioskgatan 3, S 221 85 Lund, Sweden
    Rheumatology (Oxford) 46:608-11. 2007
  9. doi request reprint Long-term mortality rate in rheumatoid arthritis patients with disease onset in the 1980s
    M C Kapetanovic
    Department of Rheumatology, Lund University, Lund, Sweden
    Scand J Rheumatol 40:433-8. 2011
  10. ncbi request reprint The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Scand J Rheumatol 36:411-7. 2007

Detail Information

Publications26

  1. pmc Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
    P Geborek
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Ann Rheum Dis 64:699-703. 2005
    ..To determine whether TNF blockers increase tumour risk in patients with RA...
  2. pmc Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden
    P Geborek
    Department of Rheumatology, Lund University Hospital, S 221 85 Lund, Sweden
    Ann Rheum Dis 61:793-8. 2002
    ....
  3. doi request reprint Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 47:495-9. 2008
    ..To identify factors predicting response to first TNF blocking treatment course in patients with established RA with a special focus on gender differences...
  4. doi request reprint Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden
    A Gulfe
    Department of Rheumatology, Lund University Hospital, Sweden
    Ann Rheum Dis 69:352-7. 2010
    ..Industry-independent health economic studies should complement studies sponsored by industry...
  5. doi request reprint Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register
    J A Karlsson
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 47:507-13. 2008
    ..To study treatment response rates of RA patients undergoing second- and third-line anti-TNF therapy and to identify baseline predictors of response to second-line treatment...
  6. doi request reprint Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register
    L E Kristensen
    South Sweden Musculoskeletal Research Centre, Lund University Hospital, Lund University, Sweden
    Arthritis Care Res (Hoboken) 62:1362-9. 2010
    ..To examine clinical characteristics as possible predictors of long-term treatment continuation with adalimumab, etanercept, and infliximab in ankylosing spondylitis (AS) patients who had never taken biologics treated in clinical practice...
  7. doi request reprint Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis
    K Eberhardt
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Scand J Rheumatol 37:109-12. 2008
    ....
  8. ncbi request reprint Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients
    M C Kapetanovic
    Department of Rheumatology, Lund University Hospital, Kioskgatan 3, S 221 85 Lund, Sweden
    Rheumatology (Oxford) 46:608-11. 2007
    ..To compare serological response to influenza vaccine in patients with long-standing rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) blockers and/or methotrexate (MTX) and controls...
  9. doi request reprint Long-term mortality rate in rheumatoid arthritis patients with disease onset in the 1980s
    M C Kapetanovic
    Department of Rheumatology, Lund University, Lund, Sweden
    Scand J Rheumatol 40:433-8. 2011
    ..To investigate the mortality rate and possible early predictive factors of mortality after 19-23 years in a cohort of patients with rheumatoid arthritis (RA) followed prospectively from disease onset...
  10. ncbi request reprint The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Scand J Rheumatol 36:411-7. 2007
    ..To compare the efficacy of adalimumab, etanercept, and infliximab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX) by calculating the number needed to treat (NNT) using three different methods...
  11. doi request reprint Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 48:243-5. 2009
    ..To study frequency of dose escalation in infliximab-treated patients and to identify possible predictors thereof...
  12. ncbi request reprint Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Ann Rheum Dis 67:364-9. 2008
    ....
  13. doi request reprint Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease
    M C Kapetanovic
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Scand J Rheumatol 39:353-9. 2010
    ....
  14. ncbi request reprint Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis
    M C Kapetanovic
    Department of Rheumatology, Lund University Hospital, Kioskgatan 3, S 221 85 Lund, Sweden
    Rheumatology (Oxford) 45:106-11. 2006
    ..To compare antibody responses to 23-valent pneumococcal vaccine (Pneumovax) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both...
  15. doi request reprint Extra-articular manifestations in a community-based sample of patients with rheumatoid arthritis: incidence and relationship to treatment with TNF inhibitors
    B M Nyhäll-Wåhlin
    Department of Rheumatology, Falun Hospital, Falun, Sweden
    Scand J Rheumatol 41:434-7. 2012
    ..To determine the incidence of severe extra-articular rheumatoid arthritis (ExRA) in a community-based cohort of RA patients, and to evaluate whether treatment with tumour necrosis factor (TNF) inhibitors has any effect on the risk of ExRA...
  16. pmc Response criteria for rheumatoid arthritis in clinical practice: how useful are they?
    A Gulfe
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Ann Rheum Dis 64:1186-9. 2005
    ....
  17. pmc Release of cartilage and bone macromolecules into synovial fluid: differences between psoriatic arthritis and rheumatoid arthritis
    B Mansson
    Department of Rheumatology, Lund University, Lund, Sweden
    Ann Rheum Dis 60:27-31. 2001
    ....
  18. pmc Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage
    E Lindqvist
    Department of Rheumatology, Lund University Hospital, S 221 85 Lund, Sweden
    Ann Rheum Dis 61:1055-9. 2002
    ..To investigate outcome as measured by health status, disease process, and damage in an unselected group of patients with early rheumatoid arthritis (RA) monitored prospectively for 10 years and to search for prognostic factors...
  19. pmc Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)
    A Scheja
    Department of Rheumatology, University Hospital, Lund, Sweden
    Arthritis Res 3:178-82. 2001
    ..Our results suggest that the propeptide, despite a shorter circulating half-time and lower plasma concentrations than vWf, is more useful in the assessment of disease activity in SSc...
  20. pmc TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden
    G Kobelt
    Karolinska Institute, Huddinge Hospital, Stockholm, Sweden
    Ann Rheum Dis 63:4-10. 2004
    ..To evaluate costs, benefits, and cost effectiveness of tumour necrosis factor inhibitor treatment over one year in routine clinical practice...
  21. pmc Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
    N Feltelius
    Swedish Medical Products Agency, PO Box 26, SE 751 03 Uppsala, Sweden
    Ann Rheum Dis 64:246-52. 2005
    ..To describe a nationwide system for postmarketing follow up of new antirheumatic drugs in Sweden, and to analyse safety and effectiveness in an etanercept treated patient cohort...
  22. ncbi request reprint Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
    M Svenson
    Institute for Inflammation Research, Rigshospitalet National University Hospital, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Rheumatology (Oxford) 46:1828-34. 2007
    ..In this study, we have compared different methods of assessing drug levels and anti-infliximab antibodies (Abs) and analysed the character of these Abs in sera of RA patients treated with infliximab for 1.5-18 months...
  23. pmc Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
    J Askling
    Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 64:1421-6. 2005
    ..Existing studies of solid cancers in rheumatoid arthritis (RA) reflect cancer morbidity up until the early 1990s in prevalent cohorts admitted to hospital during the 1980s...
  24. pmc Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
    J Askling
    Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 64:1414-20. 2005
    ..Patients with rheumatoid arthritis (RA) are at increased risk of malignant lymphomas, and maybe also of leukaemia and multiple myeloma. The effect of tumour necrosis factor (TNF) antagonists on lymphoma risk and characteristics is unclear...
  25. pmc Swedish registers to examine drug safety and clinical issues in RA
    J Askling
    Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
    Ann Rheum Dis 65:707-12. 2006
    ..The approach described is a possible prototype for long term surveillance systems needed for the safe introduction of new treatments...
  26. pmc Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales
    P Geborek
    Ann Rheum Dis 64:1805-7. 2005